Biologic Treatment for Hidradenitis Suppurativa

Kelsey S. Flood; Martina L. Porter; Alexa B. Kimball


Am J Clin Dermatol. 2019;20(5):625-638. 

In This Article


Several biologics have been studied in HS, however, adalimumab remains the only FDA-approved treatment for management of moderate-to-severe HS. Other biologics suggest therapeutic promise, but implementation of these biologics is limited by the lack of well-designed, adequately powered clinical trials to study their efficacy. In order to expand upon the therapeutic options available to HS patients, further research using validated HS scoring systems is important. Further, longitudinal studies assessing efficacy and safety over time are also of paramount importance.